Zecotek’s GFL Technology Highlighted at Photonics West Seminar in San Francisco

Zecotek’s Green Fiber Laser Technology Platform Highlighted at Laser and Photonics Marketplace in San Francisco

Singapore, February 18, 2010 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company’s proprietary green fiber laser technology platform was recently highlighted during a key note address at the Lasers and Photonics Marketplace Seminar which was held in parallel with the 2010 Photonics West Conference in San Francisco. Dr. William Telford, a staff scientist and faculty head of the National Cancer Institute, featured the Green Fiber Laser in his talk which discussed specifications of various lasers used in flow cytometry.

“Although the number of fluorescent proteins available for research has exploded in number in the past five years, most flow cytometers cannot take advantage of the opportunity to research these proteins due to laser limitations,��? said Dr. Telford. “Modern laser technology, such as Zecotek’s Green Fiber Laser, is eliminating this limitation. The broad range of operating wavelengths enables accurate matching to fluorescent targets, thus optimizing analysis.��?

Dr. Telford described Zecotek’s 550-nm green fiber laser and explained that this laser’s technology platform, utilizing a novel laser cavity design, can enable various lasers with wavelengths from 515 to 560 nm. His presentation also indicated that Zecotek’s 550-nm green fiber laser was as powerful as comparable 532-nm and 561-nm sources, but is more compatible with standard fluorescent markers.

A more detailed description of Zecotek’s Green Fiber Laser applications in flow cytometry will be available in a jointly authored paper by the National Institute of Health and Zecotek in a forthcoming edition of the journal Cytometry Part Atitled “Green Fiber Lasers: an alternative to traditional DPSS green lasers for flow cytometry��? by Dr. William G. Telford, et al.

The world market for flow cytometry systems is about $1.5 billion (about 68% of which is for instruments and 32% for chemical reagents), The market is estimated to more than double by 2015 (Source: 2008 Flow Cytometry Report, Biocompare Surveys and Reports). Approximately 1,500 to 2,000 flow cytometry units are delivered annually, many of which use several lasers to illuminate cells.

Zecotek’s visible wavelength fiber lasers have been specifically developed as higher performance, lower cost replacements for argon-ion and solid-state laser wavelengths in applications including: bio-instrumentation (DNA Sequencing, Flow Cytometry, Scanning Laser Microscopy), medicine (Ophthalmology, Dermatology, Urology), printing and imaging, inspection and measurement, laser writing and lithography, and fundamental research (Spectroscopy, Fluorescence Analysis).

About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Zecotek Photonics Inc.
Michael Minder
T: (604) 827-5212
[email protected]
CHF Investor Relations
Christopher Haldane, Account Manager
T: (416) 868-1079 x237
[email protected]

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.